JOHANNESBURG (Reuters) - Africa's first COVID-19 vaccination plant, touted last year as a trailblazer for an under-vaccinated continent frustrated by sluggish Western handouts, risks shutting down after receiving not a single order, a company executive said on Saturday.
South Africa's Aspen Pharmacare negotiated a licensing deal in November to package and sell Johnson & Johnson's COVID-19 vaccine and distribute it across Africa.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
